← Back to Clinical Trials
Recruiting NCT06180551

NCT06180551 Homburg Renal Evaluation Study on the Clinical Utility of Early AKI Diagnosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06180551
Status Recruiting
Phase
Sponsor Universität des Saarlandes
Condition Acute Kidney Injury
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2023-12-01
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
DKK-3

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2023-12-01 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Critically ill patients are at risk of developing a sudden decrease of kidney function which may be detected by a decrease in urine output or is diagnosed on the basis of blood tests for substances normally eliminated by the kidney, primarily creatinine. Because it takes about 24 hours for the creatinine level to rise, even if both kidneys have ceased to function, better markers are needed. This trial is investigating if the marker urinary dickkopf-3 (uDKK3) allows an early prediction of a sudden decrease of kidney function.

Eligibility Criteria

Inclusion Criteria: * Patients treated on the intensive care units of Saarland University Hospital. Exclusion Criteria: * Patients on renal replacement treatment before admission to the intensive care unit. * Patients with chronic kidney disease stage CKD G3b or below. * Known kidney disease. * Kidney transplantation. * Intoxications leading to dialysis treatment. * Participation in other clinical trials.

Contact & Investigator

Central Contact

Stefan Neuhaus, MD

✉ stefan.neuhaus@uks.eu

📞 +4968411615041

Principal Investigator

Stefan Neuhaus, MD

PRINCIPAL INVESTIGATOR

Universität des Saarlandes

Frequently Asked Questions

Who can join the NCT06180551 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06180551 currently recruiting?

Yes, NCT06180551 is actively recruiting participants. Contact the research team at stefan.neuhaus@uks.eu for enrollment information.

Where is the NCT06180551 trial being conducted?

This trial is being conducted at Homburg, Germany.

Who is sponsoring the NCT06180551 clinical trial?

NCT06180551 is sponsored by Universität des Saarlandes. The principal investigator is Stefan Neuhaus, MD at Universität des Saarlandes. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology